Kymera Therapeutics Inc Stock

$45.51

1.34% yesterday

Nasdaq, Jul 16, 10:00 pm CET

ISIN

US5015751044

Symbol

KYMR

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Kymera Therapeutics Inc Stock price

$45.51

+12.25 36.83% 5Y

Nasdaq, Closing price Wed, Jul 16 2025

+0.60 1.34%

ISIN

US5015751044

Symbol

KYMR

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$3.2b

Enterprise Value

$2.7b

Net debt

positive

Cash

$463.2m

Shares outstanding

65.1m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

53.5 | 42.3

EV/Sales

45.7 | 36.1

EV/FCF

negative

P/B

4.0

Financial Health

Equity Ratio

85.4%

Return on Equity

-26.8%

ROCE

-32.4%

ROIC

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

$58.9m | $74.5m

EBITDA

$-270.3m | $-311.3m

EBIT

$-278.2m | $-325.2m

Net Income

$-240.9m | $-232.1m

Free Cash Flow

$-240.0m

Growth (TTM | estimate)

Revenue

-25.8% | 58.3%

EBITDA

-59.9% | -24.9%

EBIT

-60.7% | -26.7%

Net Income

-55.8% | -3.7%

Free Cash Flow

-76.1%

EPS

$-3.0

FCF per Share

$-3.7

Short interest

14.7%

Employees

188

Rev per Employee

$250.0k

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Get Started for Free Today

Kymera Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

26 Analysts have issued a Kymera Therapeutics Inc forecast:

25x Buy

96%

More details on Analyst Estimates Including Price Targets

26 Analysts have issued a Kymera Therapeutics Inc forecast:

Buy

96%

Hold

Analyst Estimates with Stock Price Targets

Financial data from Kymera Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	59 59	26% 26% 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	65 65	15% 15% 111%
- Research and Development Expense	272 272	39% 39% 461%
EBITDA	-270 -270	60% 60% -459%
- Depreciation and Amortization	7.96 7.96	93% 93% 14%
EBIT (Operating Income) EBIT	-278 -278	61% 61% -472%
Net Profit	-241 -241	56% 56% -409%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Kymera Therapeutics Inc Stock News

Neutral

GlobeNewsWire

●

20 days ago

Kymera Therapeutics Announces Pricing of $250 Million Public Offering

WATERTOWN, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the pricing of its underwritten public offering of $250.8 million of shares of its common stock and, in lieu of common stock to certain investors, pre-f...

Neutral

GlobeNewsWire

●

21 days ago

Kymera Therapeutics Announces Proposed Public Offering

WATERTOWN, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it has commenced an underwritten public offering of $250.0 million of shares of its common stock and, in lieu of common stock to certain investors,...

Positive

Proactive Investors

●

21 days ago

Gilead partners with Kymera to develop novel cancer therapy

Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS) and Kymera Therapeutics (NASDAQ:KYMR) have entered into an exclusive option and license agreement focused on developing a novel cancer treatment targeting cyclin-dependent kinase 2 (CDK2), a protein that plays a key role in tumor growth. This collaboration aims to accelerate the development and commercialization of a new class of drugs called molecular...

More Kymera Therapeutics Inc News

Company Profile

Kymera Therapeutics, Inc. operates as a biotechnology company, which engages in curing untreatable diseases. It focuses on discovering and developing novel small molecule therapeutics. The firm's proprietary integrated degradation platform consists of informatics-driven target identification, novel E3 ligases and ligands, proprietary predictive modeling, and novel degradation tools. The company was founded by Bruce Lee Booth and Nello Mainolfi in September 2015 and is headquartered in Watertown, MA.

Head office	United States
CEO	Nello Mainolfi
Employees	188
Founded	2015
Website	www.kymeratx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now